HER2−, HR+ early breast cancer: are anthracyclines necessary?
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Previous data suggest that cardiotoxic anthracyclines (doxorubicin [Adriamycin] & epirubicin [Ellence]) may have limited value in human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC).
This phase 3 trial in patients with HER2-negative, hormone receptor-positive (HR+) EBC found that anthracycline-free chemotherapy was as effective as anthracycline-containing regimens using the prevalence of circulating tumor cells (CTCs), which indicate poor prognosis.
Why this matters
Although this study suggests that anthracycline-free regimens can be used, the authors call for efficacy analysis using full survival analysis.
Open-label, phase 3 study of 3642 patients with EBC, randomly assigned to 6 cycles anthracycline-containing chemotherapy vs anthracycline-free chemotherapy.
Main outcome measure was CTC levels using US Food and...